Other substances

AG0301-COVID19

COVID-19 candidate vaccine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
1
 Clinical trials

General information

AG0301-COVID19 is a candidate vaccine being developed by Osaka University, Anges, and Takara Bio. It is a DNA plasmid vaccine + adjuvant, based on the DNA platform. Currently, this COVID-19 candidate vaccine is in Phase I/II of clinical evaluation. 

 

Supporting references

Link Tested on Impact factor Notes Publication date
Draft landscape of COVID-19 candidate vaccines
healthy adults Jul/28/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04463472 Study of COVID-19 DNA Vaccine (AG0301-COVID19) Completed Phase 1|Phase 2 Jun/29/2020 Aug/12/2021
  • Alternative id - AG0301-COVID19-JN-01
  • Interventions - Biological: AG0301-COVID19
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Osaka City University Hospital, Osaka, Japan
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 30
  • Age - 20 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Immunogenicity|Change in GMT of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein receptor binding domain-specific antibody|Change in GMT of anti-SARS-CoV-2 B cell epitope antibody|Change in IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Adverse events
Export (.csv)